Gerhard Gründer, Prof Dr

  • 7Articles
  • 50.8KReads
  • 2008–2023Active
  • 33Collaborators
  • 212Citations

About

Gerhard Gründer, Prof Dr is affiliated with Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP), Task Force “Therapeutic Drug Monitoring”. Gerhard Gründer has authored or co-authored 7 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2008 and 2023. Their work focuses on Depression (MDD), Addiction, Dementia, Genetics, and Neurology.

Publications

JCP
Therapeutic Reference Range for Olanzapine
Systematic Review

Therapeutic Reference Range for Olanzapine

July 19, 2023

A therapeutic reference range of 20–40 ng/mL for oral and long-acting injectable olanzapine yields optimal treatment effects in schizophrenia spectrum disorders. Dose reduction is not needed above 40 ng/mL...
, , , et al
JCP
Consensus Statement

Consensus on Monitoring Blood Antipsychotic Levels

May 19, 2020

The quantification of antipsychotic levels in blood, or therapeutic drug monitoring (TDM), could aid clinicians in numerous challenging scenarios. Learn more about using TDM for dosing decisions in this...
, , , et al
JCP
Original Research

Kidney Function and Serum Risperidone Concentrations

November 26, 2019

Risperidone is mainly metabolized hepatically to its metabolite 9-hydroxyrisperidone (9-OH-RIS), which is excreted renally. This study examined how kidney function affects serum concentrations of risperidone and 9-OH-RIS in a...
, , , et al
JCP
Original Research

Duloxetine Dosing Strategies and Smoking Status

September 4, 2018

Cigarette smoking is common among individuals depression, and smoking can affect the metabolism of antidepressant medications. Read this article to learn dosing strategies that physicians can employ when treating...
, , , et al
JCP
Original Research

Venlafaxine and O-Desmethylvenlafaxine Concentrations in Plasma and Cerebrospinal Fluid

August 19, 2014

, , , et al
JCP
Case Report

Cytochrome P450 2D6 Polymorphism and Its Impact on Decision-Making in Psychopharmacotherapy: Finding the Right Way in an Ultrarapid Metabolizing Patient

November 15, 2011

, , , et al
JCP
Letter to the Editor

Toxic Psychosis After Intake of the Hallucinogen Salvinorin A

September 30, 2008

,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe